JP2012507278A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507278A5
JP2012507278A5 JP2011533932A JP2011533932A JP2012507278A5 JP 2012507278 A5 JP2012507278 A5 JP 2012507278A5 JP 2011533932 A JP2011533932 A JP 2011533932A JP 2011533932 A JP2011533932 A JP 2011533932A JP 2012507278 A5 JP2012507278 A5 JP 2012507278A5
Authority
JP
Japan
Prior art keywords
amino acid
rnaset2
seq
truncated
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011533932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507278A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2009/001012 external-priority patent/WO2010049933A1/en
Publication of JP2012507278A publication Critical patent/JP2012507278A/ja
Publication of JP2012507278A5 publication Critical patent/JP2012507278A5/ja
Pending legal-status Critical Current

Links

JP2011533932A 2008-10-30 2009-10-29 短縮型ヒトrnaset2の大腸菌における効率的発現 Pending JP2012507278A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19313408P 2008-10-30 2008-10-30
US61/193,134 2008-10-30
PCT/IL2009/001012 WO2010049933A1 (en) 2008-10-30 2009-10-29 Efficient expression of truncated human rnaset2 in e. coli

Publications (2)

Publication Number Publication Date
JP2012507278A JP2012507278A (ja) 2012-03-29
JP2012507278A5 true JP2012507278A5 (cg-RX-API-DMAC7.html) 2012-12-13

Family

ID=41694413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533932A Pending JP2012507278A (ja) 2008-10-30 2009-10-29 短縮型ヒトrnaset2の大腸菌における効率的発現

Country Status (8)

Country Link
US (1) US20110207667A1 (cg-RX-API-DMAC7.html)
EP (1) EP2346993A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012507278A (cg-RX-API-DMAC7.html)
AU (1) AU2009309277A1 (cg-RX-API-DMAC7.html)
CA (1) CA2739705A1 (cg-RX-API-DMAC7.html)
EA (1) EA201100610A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010049933A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102615B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127752A1 (en) * 2012-02-29 2013-09-06 F. Hoffmann-La Roche Ag Method for reduction of 1->3 reading frame shifts
EP3004339B1 (en) * 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021830A1 (en) * 1999-09-24 2001-03-29 Ambion, Inc. Nuclease inhibitor cocktail
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2006035439A2 (en) * 2004-09-29 2006-04-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Recombinant human t2 rnase and uses thereof
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof

Similar Documents

Publication Publication Date Title
PH12013500050A1 (en) Anticancer fusion protein
HRP20201973T1 (hr) Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2019015502A (es) L-asparaginasa modificada.
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
IL199263A (en) Glucagon peptide with enhanced solubility, pharmaceutical composition containing it and its uses for drug preparation
JP2011528895A5 (cg-RX-API-DMAC7.html)
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
JP2015510393A5 (cg-RX-API-DMAC7.html)
JP2014529399A5 (cg-RX-API-DMAC7.html)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
HRP20201081T1 (hr) Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe
IN2014DN09963A (cg-RX-API-DMAC7.html)
JP2015533791A5 (cg-RX-API-DMAC7.html)
JP2012529293A5 (cg-RX-API-DMAC7.html)
JP2012102105A5 (cg-RX-API-DMAC7.html)
IL269187B1 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
JP2011521661A5 (cg-RX-API-DMAC7.html)
JP2015511599A5 (cg-RX-API-DMAC7.html)
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
JP2008545393A5 (cg-RX-API-DMAC7.html)
MX2009007261A (es) Vacuna de peptido foxp3.
JP2017513849A5 (cg-RX-API-DMAC7.html)
CN102311500B (zh) 一种抗病毒融合蛋白及其应用
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение